0.69
-30.32%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Skye Bioscience
From its filings with the US Securities and Exchange Commission
Skye Bioscience is based in San Diego, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker SKYE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $55.9m. At that date it held total assets of $28.3m and shareholders' equity of $20.0m.
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.
We believe there is a growing demand for therapies that offer improved safety, efficacy, tolerability, quality of life and long-term health outcomes while addressing the limitations of currently approved treatments. Our objective is to drive innovation in the treatment landscape for obesity, overweight and metabolic disorders by developing potential first-in-class therapies that meet significant unmet medical needs globally.
We completed the acquisition of Bird Rock Bio, Inc. (“Bird Rock”), a privately held, clinical-stage biotechnology company, in August 2023. Through this transaction, we acquired nimacimab, a humanized IgG4 negative allosteric modulating ("NAM") antibody that specifically binds to the CB1 receptor with no cross-reactivity to certain other GPCRs, including cannabinoid receptor 2 ("CB2").
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Feb 2014
- Employees
- 11
- Website
- skyebioscience.com ↗
- Head office
- 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Paul GraysonIndependent Chairman of the Board$2.2m
- Dr. Punit DhillonPresident, Chief Executive Officer, Director, since 2017$6.1m
- Ms. Kaitlyn ArsenaultChief Financial Officer$2.3m
- Mr. Tuan Tu DiepChief Operating Officer$2.2m
- Mr. Christopher TwittyChief Scientific Officer
- Dr. Puneet AroraChief Medical Officer
- Mr. Andrew SchwabDirector$685,140
- Dr. Deborah CharychIndependent Director$690,181
- Dr. Annalisa JenkinsIndependent Director$749,743
- Dr. Karen SmithIndependent Director$491,328
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 21
- Environment
- 21
- Social
- 36
- Governance
- 7
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in the Biotechnology sector with a focus on cannabinoid derivatives.
- Lead product candidate SBI-100 OE is in Phase I trial for glaucoma treatment.
- Develops multiple formulations including SBI-200 with potential therapeutic applications.
Weaknesses
- Limited employee count of 11 full-time staff.
- IPO occurred in 2014, indicating a relatively early stage company.
- Relies on a single lead product candidate for clinical development.
Opportunities
- Potential to treat ophthalmic disorders with SBI-100 OE and SBI-200.
- Expanding therapeutic applications for SBI-200 including eye diseases.
- Conducting first-in-human trials in Australia for SBI-100 OE.
Threats
- Dependence on a single product candidate for development.
- Early stage company with IPO in 2014 may face funding challenges.
- Competition in biopharmaceutical sector for cannabinoid-based treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.